MAP2K7 and metastatic melanoma: Starting from the rationale that BRAF and MEK inhibitors have the ability to increase T cell responses through a variety of immunological changes, researchers combined BRAF/MEK inhibitors and anti-PD1 antibodies to achieve a synergistic effect in the treatment of metastatic melanoma.